Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Oberhausen

10 clinical trials in Oberhausen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Oberhausen at a glance
10
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

10 trials in Oberhausen

Open in trial search

A double‑blind, placebo‑controlled trial of oral BI 1015550 in patients with systemic sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 1015550
  • Sponsor:Boehringer Ingelheim Espana S.A.

Phase 3 Study of Enpatoran in Patients with Active Cutaneous Lupus Erythematosus (with or without Systemic Disease)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Merck Healthcare KGaA

Evaluation of Cemiplimab Safety and Effectiveness as First Treatment for Advanced Basal Cell Carcinoma in Adult Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Study on Acalabrutinib, Obinutuzumab, and Venetoclax for Untreated High-Risk Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:University Of Cologne

Study on the Effects of Sirolimus and Drug Combination for Children Under 4 Months with Tuberous Sclerosis Complex

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Carbamazepine
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Study on Stopping CDK4/6 Inhibitors in Patients with Metastatic HR Positive, HER2 Negative Breast Cancer Using Abemaciclib, Letrozole, and Fulvestrant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Systemic scleroderma

Not yet recruiting

Lebrikizumab in Adults with Moderate to Severe Localized Scleroderma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study of luspatercept in patients with low-risk myelodysplastic syndrome (MDS) who do not require blood transfusions and have not received erythropoiesis treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:Universitaet Leipzig

Colon cancer stage II+1

Not recruiting

Study on Adjuvant Therapy with Capecitabine for Stage II Colon and Rectal Cancer Patients with Positive ctDNA After Tumor Removal

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Technische Universitat Dresden

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Other cities in Germany

The busiest research cities in the country

All 513 cities in Germany

Clinical research in Oberhausen

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on basal cell carcinoma and advanced breast cancer treatments. Studies evaluate novel therapeutic approaches including CDK4/6 inhibitors for metastatic breast cancer and new first-line treatments for skin cancer.

  • Advanced Basal Cell Carcinoma
  • Metastatic Breast Cancer
  • Colon Cancer Management

Research includes evaluation of treatment discontinuation strategies and disease control monitoring.

02 Dermatology and Immunology

Clinical research examining new treatments for atopic dermatitis, evaluating the effectiveness of targeted therapies in managing moderate-to-severe cases over a 24-week period.

  • Moderate-to-Severe Atopic Dermatitis
  • Immune System Responses
  • Long-term Disease Management

Focus on improving disease severity and symptom control in both adults and adolescents.

03 Hematology Studies

Advanced research in blood disorders, including studies on chronic lymphocytic leukemia and myelodysplastic syndromes. Trials evaluate combination therapies and novel treatment approaches.

  • High-Risk CLL Treatment
  • MDS Management
  • Anemia Interventions

Investigation of targeted therapies for better patient outcomes in blood disorders.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.